Literature DB >> 11307816

Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage.

S Y Lee1, S K Chang, I H Lee, Y M Kim, S I Chung.   

Abstract

The impact of clot stability affecting the vasculopathy and tissue necrosis in Shwartzman reaction was investigated using plasma Factor XIII A2-depleted rabbit (FXIII-DR). Plasma Factor XIIIA2 (FXIIIA2) was depleted by infusion of the mono-specific goat anti-rabbit FXIIIA2 IgG. Generalized Shwartzman reaction (GSR) was induced by priming and challenged by i.v. injection of LPS and local Shwartzman reaction (LSR) was primed by intradermal injection of LPS and challenged by i.v. injection of LPS. Histological examination of the GSR animals showed, extensive thrombi accumulation in renal tubules and bilateral cortical necrosis of kidney in 8 out of 10 rabbits but none in the FXIII-DR. Fibrinogen levels were elevated to 3 approximately 4 fold at 24 h and lowered at 48 h whereas a steady rise was seen in the FXIII-DR. FDP levels in GSR animals were significantly elevated at 24 h and further increased at 48 h but only slightly elevated in the FXIII-DR. Examination of the LSR tissues after 48 h showed an acute onset of progressive cutaneous vascular thrombosis, purpura, and secondary hemorrhagic necrosis whereas neither fibrin deposit nor necrosis of tissue were detected in FXIII-DR despite of an early edema formation. Fibrinogen levels were also increased two fold at 24 h but returned to basal levels at 48 h in control LSR animals but not affected at all in FXIII-DR. These results suggest that during the severe inflammatory conditions such as sepsis, the fibrinolytic system is functionally sufficient to dissipate the pathogenic accumulation of disseminated intravascular clots and exudated fibrin clots if those clots were prevented from getting crosslinked in plasma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307816

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia.

Authors:  Andrea T Obi; Elizabeth Andraska; Yogendra Kanthi; Chase W Kessinger; Megan Elfline; Cathy Luke; Teruna J Siahaan; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  Thromb Haemost       Date:  2016-12-15       Impact factor: 5.249

2.  Ethacrynic acid is an inhibitor of human factor XIIIa.

Authors:  Srabani Kar; Kayla Vu; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  BMC Pharmacol Toxicol       Date:  2022-06-01       Impact factor: 2.605

3.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

4.  Natural selection and the molecular basis of electrophoretic variation at the coagulation F13B locus.

Authors:  Anthony W Ryan; David A Hughes; Kun Tang; Dermot P Kelleher; Thomas Ryan; Ross McManus; Mark Stoneking
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

5.  Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia.

Authors:  Jürgen Birnbaum; Ortrud Vargas Hein; Carsten Lührs; Oskar Rückbeil; Claudia Spies; Sabine Ziemer; Matthias Gründling; Taras Usichenko; Konrad Meissner; Dragan Pavlovic; Wolfgang J Kox; Christian Lehmann
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

6.  Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction.

Authors:  Sjoukje H Slofstra; Hugo ten Cate; C Arnold Spek
Journal:  Thromb J       Date:  2006-08-24

7.  Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).

Authors:  Ralf Pasternack; Christian Büchold; Robert Jähnig; Christiane Pelzer; Michael Sommer; Andreas Heil; Peter Florian; Götz Nowak; Uwe Gerlach; Martin Hils
Journal:  J Thromb Haemost       Date:  2019-10-23       Impact factor: 5.824

8.  Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals.

Authors:  Andrea Beyerle; Cristina Solomon; Gerhard Dickneite; Eva Herzog
Journal:  Pharmacol Res Perspect       Date:  2016-03-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.